{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:11:30Z","timestamp":1793131890140,"version":"4.5.0"},"reference-count":32,"publisher":"Baishideng Publishing Group Inc.","issue":"36","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJG"],"published-print":{"date-parts":[[2009]]},"DOI":"10.3748\/wjg.15.4511","type":"journal-article","created":{"date-parts":[[2009,9,25]],"date-time":"2009-09-25T13:18:11Z","timestamp":1253884691000},"page":"4511","source":"Crossref","is-referenced-by-count":98,"title":["EGFR and HER2 expression in advanced biliary tract cancer"],"prefix":"10.3748","volume":"15","author":[{"given":"Jan","family":"Harder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Waiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Otto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Geissler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Olschewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Weinhold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert E","family":"Blum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Schmitt-Graeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver G","family":"Opitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Malhi H, Gores GJ. Review article: the modern diagnosis and therapy of cholangiocarcinoma. Aliment Pharmacol Ther 2006;23:1287-1296.","DOI":"10.1111\/j.1365-2036.2006.02900.x"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005;366:1303-1314.","DOI":"10.1016\/S0140-6736(05)67530-7"},{"key":"ref3","unstructured":"Ménard S, Casalini P, Campiglio M, Pupa SM, Tagliabue E. Role of HER2\/neu in tumor progression and therapy. Cell Mol Life Sci 2004;61:2965-2978."},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Hudis CA. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51.","DOI":"10.1056\/NEJMra043186"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Hudis CA. Trastuzumab adds to adjuvant chemotherapy for resected HER2-positive breast cancer. Nat Clin Pract Oncol 2006;3:12-13.","DOI":"10.1038\/ncponc0401"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Press MF, Lenz HJ. EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. Drugs 2007;67:2045-2075.","DOI":"10.2165\/00003495-200767140-00006"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Ooi A, Takehana T, Li X, Suzuki S, Kunitomo K, Iino H, Fujii H, Takeda Y, Dobashi Y. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod Pathol 2004;17:895-904.","DOI":"10.1038\/modpathol.3800137"},{"key":"ref8","unstructured":"Huang TW, Wang CH, Hsieh CB. Effects of the anti-epidermal growth factor receptor antibody cetuximab on cholangiocarcinoma of the liver. Onkologie 2007;30:129-131."},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Bralet MP, Bellin MF, Guettier C, Adam R, Paule B. Response to cetuximab and gemcitabine-oxaliplatin in an advanced case of intrahepatic cholangiocarcinoma. Clin Oncol (R Coll Radiol) 2006;18:426.","DOI":"10.1016\/j.clon.2006.03.003"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Sprinzl MF, Schimanski CC, Moehler M, Schadmand-Fischer S, Galle PR, Kanzler S. Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report. BMC Cancer 2006;6:190.","DOI":"10.1186\/1471-2407-6-190"},{"key":"ref11","unstructured":"Büchler P, Reber HA, Eibl G, Roth MA, Büchler MW, Friess H, Isacoff WH, Hines OJ. Combination therapy for advanced pancreatic cancer using Herceptin plus chemotherapy. Int J Oncol 2005;27:1125-1130."},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Büchler P, Reber HA, Büchler MC, Roth MA, Büchler MW, Friess H, Isacoff WH, Hines OJ. Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin). J Gastrointest Surg 2001;5:139-146.","DOI":"10.1016\/S1091-255X(01)80025-1"},{"key":"ref13","unstructured":"Kiguchi K, Carbajal S, Chan K, Beltrán L, Ruffino L, Shen J, Matsumoto T, Yoshimi N, DiGiovanni J. Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Res 2001;61:6971-6976."},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Aishima SI, Taguchi KI, Sugimachi K, Shimada M, Sugimachi K, Tsuneyoshi M. c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. Histopathology 2002;40:269-278.","DOI":"10.1046\/j.1365-2559.2002.00353.x"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Altimari A, Fiorentino M, Gabusi E, Gruppioni E, Corti B, D'Errico A, Grigioni WF. Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours. Dig Liver Dis 2003;35:332-338.","DOI":"10.1016\/S1590-8658(03)00077-X"},{"key":"ref16","unstructured":"Chow NH, Huang SM, Chan SH, Mo LR, Hwang MH, Su WC. Significance of c-erbB-2 expression in normal and neoplastic epithelium of biliary tract. Anticancer Res 1995;15:1055-1059."},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Endo K, Yoon BI, Pairojkul C, Demetris AJ, Sirica AE. ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology 2002;36:439-450.","DOI":"10.1053\/jhep.2002.34435"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Terada T, Ashida K, Endo K, Horie S, Maeta H, Matsunaga Y, Takashima K, Ohta T, Kitamura Y. c-erbB-2 protein is expressed in hepatolithiasis and cholangiocarcinoma. Histopathology 1998;33:325-331.","DOI":"10.1046\/j.1365-2559.1998.00496.x"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Ukita Y, Kato M, Terada T. Gene amplification and mRNA and protein overexpression of c-erbB-2 (HER-2\/neu) in human intrahepatic cholangiocarcinoma as detected by fluorescence in situ hybridization, in situ hybridization, and immunohistochemistry. J Hepatol 2002;36:780-785.","DOI":"10.1016\/S0168-8278(02)00057-0"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Thursz MR, Wasan H. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 2002;51 Suppl 6:VI1-VI9.","DOI":"10.1136\/gut.51.suppl_6.vi1"},{"key":"ref21","unstructured":"Ooi A, Kobayashi M, Mai M, Nakanishi I. Amplification of c-erbB-2 in gastric cancer: detection in formalin-fixed, paraffin-embedded tissue by fluorescence in situ hybridization. Lab Invest 1998;78:345-351."},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Takehana T, Kunitomo K, Suzuki S, Kono K, Fujii H, Matsumoto Y, Ooi A. Expression of epidermal growth factor receptor in gastric carcinomas. Clin Gastroenterol Hepatol 2003;1:438-445.","DOI":"10.1016\/S1542-3565(03)00219-2"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Ito Y, Takeda T, Sasaki Y, Sakon M, Yamada T, Ishiguro S, Imaoka S, Tsujimoto M, Higashiyama S, Monden M. Expression and clinical significance of the erbB family in intrahepatic cholangiocellular carcinoma. Pathol Res Pract 2001;197:95-100.","DOI":"10.1078\/0344-0338-00016"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Yoshikawa D, Ojima H, Iwasaki M, Hiraoka N, Kosuge T, Kasai S, Hirohashi S, Shibata T. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer 2008;98:418-425.","DOI":"10.1038\/sj.bjc.6604129"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Nehls O, Oettle H, Hartmann JT, Hofheinz RD, Hass HG, Horger MS, Koppenhöfer U, Hochhaus A, Stieler J, Trojan J. Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer 2008;98:309-315.","DOI":"10.1038\/sj.bjc.6604178"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Harder J, Riecken B, Kummer O, Lohrmann C, Otto F, Usadel H, Geissler M, Opitz O, Henss H. Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. Br J Cancer 2006;95:848-852.","DOI":"10.1038\/sj.bjc.6603334"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Voravud N, Foster CS, Gilbertson JA, Sikora K, Waxman J. Oncogene expression in cholangiocarcinoma and in normal hepatic development. Hum Pathol 1989;20:1163-1168.","DOI":"10.1016\/S0046-8177(89)80006-1"},{"key":"ref28","unstructured":"Yau TK, Sze H, Soong IS, Hioe F, Khoo US, Lee AW. HER2 overexpression of breast cancers in Hong Kong: prevalence and concordance between immunohistochemistry and in-situ hybridisation assays. Hong Kong Med J 2008;14:130-135."},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Carlson RW, Moench SJ, Hammond ME, Perez EA, Burstein HJ, Allred DC, Vogel CL, Goldstein LJ, Somlo G, Gradishar WJ, Hudis CA, Jahanzeb M, Stark A, Wolff AC, Press MF, Winer EP, Paik S, Ljung BM. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw 2006;4 Suppl 3:S1-S22; quiz S23-S24.","DOI":"10.6004\/jnccn.2006.2003"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Kobayashi M, Ooi A, Oda Y, Nakanishi I. Protein overexpression and gene amplification of c-erbB-2 in breast carcinomas: a comparative study of immunohistochemistry and fluorescence in situ hybridization of formalin-fixed, paraffin-embedded tissues. Hum Pathol 2002;33:21-28.","DOI":"10.1053\/hupa.2002.30185"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Hirashima N, Takahashi W, Yoshii S, Yamane T, Ooi A. Protein overexpression and gene amplification of c-erb B-2 in pulmonary carcinomas: a comparative immunohistochemical and fluorescence in situ hybridization study. Mod Pathol 2001;14:556-562.","DOI":"10.1038\/modpathol.3880350"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Nakazawa K, Dobashi Y, Suzuki S, Fujii H, Takeda Y, Ooi A. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol 2005;206:356-365.","DOI":"10.1002\/path.1779"}],"container-title":["World Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v15\/i36\/4511.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T07:00:01Z","timestamp":1633935601000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v15\/i36\/4511.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009]]},"references-count":32,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.3748\/wjg.15.4511","relation":{},"ISSN":["1007-9327"],"issn-type":[{"value":"1007-9327","type":"print"}],"subject":[],"published":{"date-parts":[[2009]]}}}